Detalhe da pesquisa
1.
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.
Cell;
152(4): 714-26, 2013 Feb 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23415222
2.
Mechanism of EBV inducing anti-tumour immunity and its therapeutic use.
Nature;
590(7844): 157-162, 2021 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33361812
3.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med;
388(4): 319-332, 2023 01 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36511784
4.
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
N Engl J Med;
389(1): 33-44, 2023 Jul 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37407001
5.
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
Blood;
143(16): 1616-1627, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38215395
6.
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Blood;
142(8): 687-699, 2023 08 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37390310
7.
Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.
Blood;
142(5): 421-433, 2023 08 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37146250
8.
Growth dynamics in naturally progressing chronic lymphocytic leukaemia.
Nature;
570(7762): 474-479, 2019 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31142838
9.
Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Blood;
139(5): 686-689, 2022 02 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34788401
10.
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
Ann Hematol;
103(1): 185-198, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37851072
11.
Clinical Risks for Chronic Lymphocytic Leukemia.
J Natl Compr Canc Netw;
22(3)2024 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38626793
12.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol;
20(12): 717-726, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38088119
13.
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Mol Cancer;
22(1): 138, 2023 08 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37596643
14.
Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.
Blood;
138(1): 44-56, 2021 07 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33684943
15.
Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
Blood;
137(24): 3327-3338, 2021 06 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33786588
16.
miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
Blood;
137(18): 2481-2494, 2021 05 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33171493
17.
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Haematologica;
108(1): 9-21, 2023 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35899388
18.
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
Nature;
542(7642): 489-493, 2017 02 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28199309
19.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol;
23(8): 1031-1043, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35810754
20.
Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.
Br J Haematol;
197(2): 207-211, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35170759